Publication: Adjuvant or salvage radiotherapy in postoperative prostate cancer
Program
KU-Authors
KU Authors
Co-Authors
Kuban, Deborah A.
Publication Date
Language
Type
Embargo Status
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Prostate-specific antigen (PSA) screening increased the diagnosis of prostate cancer at a localized stage to be treated with a curative intent; approximately half of them undergo radical prostatectomy, and roughly one third of surgically treated patients are expected to experience a recurrence in 10 years' follow-up. Once PSA failure occurs, many develop distant metastases at a median of 8 years and afterward followed by cancer-related death at a median of 5 years. Biochemical failure risk after radical prostatectomy is mainly expected mostly in men with any of the following features: detectable postoperative PSA, positive surgical margins, extraprostatic extension of tumor (T3a), seminal vesicle invasion (T3b), and Gleason score ≥ 8. The radiotherapy in the undetectable PSA environment (<0.01 ng/mL) within 4 months after prostatectomy is termed as "adjuvant," while radiotherapy in rising PSA within any time after prostatectomy is defined as "salvage."
Source
Publisher
Springer
Subject
Oncology, Urology, Nephrology
Citation
Has Part
Source
Principles and Practice of Urooncology: Radiotherapy, Surgery and Systemic Therapy
Book Series Title
Edition
DOI
10.1007/978-3-319-56114-1_17